Equity Overview
Price & Market Data
Price: $3.15
Daily Change: -$0.04 / 1.27%
Daily Range: $3.14 - $3.23
Market Cap: $246,099,429
Daily Volume: 173,959
Performance Metrics
1 Week: 1.94%
1 Month: -6.80%
3 Months: -4.26%
6 Months: -0.63%
1 Year: 6.42%
YTD: -6.80%
Company Details
Employees: 56
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.